Raptim Insights

In the rapidly evolving landscape of medical research, the integrity of data stands as the […]

The journey of developing a new drug is as daunting as it is essential. On average, it takes more than a decade and billions of dollars to shepherd a single compound …

Imagine a promising new compound developed in a state-of-the-art laboratory, potentially life-saving, backed by years of preclinical research, and loaded with therapeutic potential.

What if the next breakthrough drug development doesn’t just come from a lab, but from how we rethink the clinical trial itself?

When we think of medicines and drug interactions, we often picture pills, syrups, or injectables. But at the heart of every drug lies a powerful substance doing the actual therapeutic work — the Active Pharmaceutical Ingredient (API).

Chimeric Antigen Receptor (CAR) T-cell therapies represent one of the most advanced, complex, and personalized treatment frontiers in modern medicine.

In recent years, precision medicine has moved from a futuristic concept to a clinical and commercial imperative. At the heart of this transformation lies a radical shift: moving from one-size-fits-all therapies to personalized treatments

We are pleased to announce a significant regulatory achievement for one of our pivotal clinical programs, the Phase III endpoint bioequivalence (BE) study

Personalized medicine is transforming healthcare by tailoring treatments to an individual’s genetic, environmental, and lifestyle

Phase I clinical trials are the cornerstone of drug development, focusing primarily on assessing safety,

Introduction Human Immunodeficiency Virus (HIV) remains one of the most pressing global health concerns. Despite

In the field of dermatological drug development, the importance of accurately assessing the performance of